Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumera I Ilyas

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Hepatology (Baltimore, Md.)|November 14, 2025
A strategic plan of RETREAT: Time to translate validation into actionZhihao Li, Sumera I Ilyas
Hepatology (Baltimore, Md.)|November 14, 2025
Starve the tumor, fuel the immune fire: Short-term starvation enhances checkpoint blockade via macrophage reprogramming in HCCYawen Dong, Sumera I Ilyas
Hepatology (Baltimore, Md.)|June 19, 2025
The dynamic duo: How tumor-associated macrophages and tumor cells team up in cholangiocarcinomaBinbin Li, Sumera I Ilyas
Hepatology (Baltimore, Md.)|January 21, 2025
Unveiling the immune landscape of IDH1 -mutant cholangiocarcinoma: Pathways to new therapiesBinbin Li, Sumera I Ilyas
Hepatology (Baltimore, Md.)|November 14, 2025
It's not you, it's MET: When MASH gets personalEnis H Ozmert, Sumera I Ilyas
Hepatology (Baltimore, Md.)|January 15, 2026
MASLD: To screen or not to screen-That is the questionJack W Sample, Sumera I Ilyas
Hepatology (Baltimore, Md.)|December 16, 2024
The clot and the complicated consultDaniel D Penrice, Sumera I Ilyas
Hepatology (Baltimore, Md.)|October 21, 2019
The Two Faces of Relaxin in Cancer: Antitumor or Protumor?Sumera I Ilyas, Gregory J Gores
Gastroenterology|October 22, 2013
Pathogenesis, diagnosis, and management of cholangiocarcinomaSumera I Ilyas, Gregory J Gores
Hepatology (Baltimore, Md.)|April 18, 2025
Obesity and the iron liver: A rusty secretDaniel D Penrice, Sumera I Ilyas
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Hepatology (Baltimore, Md.)|November 14, 2025
A strategic plan of RETREAT: Time to translate validation into actionZhihao Li, Sumera I Ilyas
Hepatology (Baltimore, Md.)|November 14, 2025
Starve the tumor, fuel the immune fire: Short-term starvation enhances checkpoint blockade via macrophage reprogramming in HCCYawen Dong, Sumera I Ilyas
Hepatology (Baltimore, Md.)|June 19, 2025
The dynamic duo: How tumor-associated macrophages and tumor cells team up in cholangiocarcinomaBinbin Li, Sumera I Ilyas
Hepatology (Baltimore, Md.)|January 21, 2025
Unveiling the immune landscape of IDH1 -mutant cholangiocarcinoma: Pathways to new therapiesBinbin Li, Sumera I Ilyas
Hepatology (Baltimore, Md.)|November 14, 2025
It's not you, it's MET: When MASH gets personalEnis H Ozmert, Sumera I Ilyas
Hepatology (Baltimore, Md.)|January 15, 2026
MASLD: To screen or not to screen-That is the questionJack W Sample, Sumera I Ilyas
Hepatology (Baltimore, Md.)|December 16, 2024
The clot and the complicated consultDaniel D Penrice, Sumera I Ilyas
Hepatology (Baltimore, Md.)|October 21, 2019
The Two Faces of Relaxin in Cancer: Antitumor or Protumor?Sumera I Ilyas, Gregory J Gores
Gastroenterology|October 22, 2013
Pathogenesis, diagnosis, and management of cholangiocarcinomaSumera I Ilyas, Gregory J Gores
Hepatology (Baltimore, Md.)|April 18, 2025
Obesity and the iron liver: A rusty secretDaniel D Penrice, Sumera I Ilyas
Pageof 9